Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Ibrutinib, Venetoclax and Adverse Cardiovascular Events
Author(s): Roberta Esposito , Pierantonio Menna , Emanuela Salvatorelli , et al Added: 7 months ago

CV Disease in Special Populations

Prevention & Chronic Conditions
Masterclass on Achievement in the Face of Adversity with Dr Eugene Braunwald
Author(s): Eugene Braunwald , Harriette Van Spall Added: 3 weeks ago
In this Radcliffe Cardiology Masterclass, Dr Harriette Van Spall (McMaster University, Canada) sits down with cardiology legend Dr Eugene Braunwald (Harvard Medical School, TIMI Study Group) to explore his life, landmark research, and advice for the next generation of cardiovascular clinicians and scientists. This discussion was originally recorded in 2021, and we share it now in remembrance of… View more

Intervention

Prevention & Chronic Conditions
30th Annual Meeting of the ISCP
Author(s): Jordi Cahís , Pablo Carrión-Montaner , Jordi Sans , et al Added: 1 month ago

Prevention & Chronic Conditions

Heart Failure
HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device
Author(s): Michael R Zile Added: 2 years ago
HFA 24 - We are joined onsite by Dr Michael Zile (Medical University of South Carolina, US) to discuss the outcomes of the RELIEVE-HF trial.RELIEVE-HF is designed to evaluate the safety and effectiveness of the V-Wave interatrial shunt system in patients with heart failure. 605 participants with New York Heart Association (NYHA) functional class II, class III or class IV heart failure, who had… View more

Heart Failure
EASD 24: Effectiveness of Empagliflozin and GLP1s
Author(s): Phyo Htoo Added: 1 year ago
EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes.Interview Questions:1. What was the reasoning for this study?2. What was the patient population and study design… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
30th Annual Meeting of the ISCP
Author(s): Daniel García Iglesias , Fernando López Iglesias , Rodrigo Ariel di Massa , et al Added: 1 month ago

Imaging & Diagnostics

Prevention & Chronic Conditions
30th Annual Meeting of the ISCP
Author(s): Jessica Ares-Blanco , Miguel García-Villarino , Carmen Lambert , et al Added: 1 month ago

Prevention & Chronic Conditions

Demographic
30th Annual Meeting of the ISCP
Author(s): Raúl Ludeña , Raúl Ptaszynski Lanza , Beatriz Nieves Ureña , et al Added: 1 month ago

Prevention & Chronic Conditions
30th Annual Meeting of the ISCP
Author(s): Jordi Cahís , Pablo Carrión-Montaner , Jordi Sans , et al Added: 1 month ago

Prevention & Chronic Conditions
ERA 25: eGFR Dips and Disease Severity on Empagliflozin
Author(s): Added: 11 months ago
ERA 2025 - Results from a meta-analysis of trials including EMPA-KIDNEY show the treatment effect of empagliflozin is not modified by level of predicted acute eGFR dip.Dr Natalie Staplin (University of Oxford, Oxford, UK) joins us to discuss findings from a meta-analysis of four trials, including the EMPA-KIDNEY trial (NCT03594110), investigating the impact of acute eGFR dips and markers of… View more

Cardiovascular Kidney Metabolic